Kareus & Quintiles Ink Strategic Development Pact

Under the terms of the alliance, Quintiles will make an undisclosed investment in Kareus through an equity investment and access to clinical service on a shared-risk basis.

Kareus Therapeutics SA, the company focused on the development of novel therapeutics to address high unmet medical need, has formed a strategic alliance with Quintiles to progress the development of two of Kareus’ preclinical programs through clinical trials.

Under the terms of the alliance, Quintiles will make an undisclosed investment in Kareus through an equity investment and access to clinical service on a shared-risk basis. Kareus plans to submit an IND application for KU-046, a new chemical entity for the treatment of Alzheimer’s disease. Kareus has also identified a lead series of molecules for the treatment of Type-2 diabetes and will select a clinical candidate for development later in 2011. Quintiles will conduct Phase I trials for both KU-046 and the diabetes candidate.